People with HIV who took the antiretroviral drug abacavir (Ziagen) had an increased risk of major adverse cardiovascular events (MACE), according to an exploratory analysis of the REPRIEVE trial.
Past use of abacavir increased the risk of MACE by 50% (risk-adjusted HR 1.50, 95% CI 1.04-2.15) and current use increased MACE risk by 42% (risk-adjusted HR 1.42, 95% CI 1.00-2.00), reported Carl Fichtenbaum, MD, of the University of Cincinnati, at the International AIDS Conference in Munich.
Read the full article here.
